Adaptimmune Therapeutics plc ADAP announced that its strategic collaboration with Roche’s RHHBY Genentech has been terminated. Shares of ADAP were down 10% on the news. Both companies ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1.91, with a high estimate of $3.00 and a low estimate of $1.40. A negative shift in ...

After the market closed on 3/24/25, Adaptimmune (NASDAQ:ADAP) filed the company’s Form 10-K Annual Report. ADAP reported a net loss of $74.2 million for 4Q24, or $(0.05) per diluted ordinary ...

Wells Fargo analyst Yanan Zhu maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) yesterday and set a price target of $1.50. The company’s shares closed yesterday at ...

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade FDA approves Adaptimmune Therapeutics' Tecelra ...

Pre-market open on 3/20/25, Adaptimmune (NASDAQ:ADAP) provided a business update for 4Q24 (in lieu of financial results for the quarter/full year to be released in conjunction with the company’s ...

In a report released yesterday, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report). The company’s shares closed yesterday at ...

Shares of NASDAQ ADAP opened at $0.25 on Tuesday. Adaptimmune Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.48. The company has a quick ratio of 3.82, a current ratio of 3.85 ...